T. Khanh

Vietnam National University Ho Chi Minh City

Also affiliated with Brigham and Women's Hospital, Pham Ngoc Thach University of Medicine, Ho Chi Minh City International University, Moderna Therapeutics (United States), Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors”.

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0.546DataRank · unranked

37 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0.457DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2145

N/A

0.416DataRank · unranked

15 citations

Naoko Takebe, Shivaani Kummar, Albiruni R. Abdul Razak, Sant P. Chawla, Suzanne George +13 more

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

Investigational New Drugs(2021)10.1007/s10637-021-01138-x

N/A

0.312DataRank · unranked

7 citations

Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young Ho Lee, Donald P. Bottaro +11 more

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1850

N/A

0DataRank · unranked

1 citations

T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes +13 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more